Reprint
Radiopharmaceuticals for PET Imaging - Issue A
Edited by
December 2020
212 pages
- ISBN978-3-03943-242-4 (Hardback)
- ISBN978-3-03943-243-1 (PDF)
This is a Reprint of the Special Issue Radiopharmaceuticals for PET Imaging - Issue A that was published in
Chemistry & Materials Science
Medicine & Pharmacology
Summary
Positron emission tomography (PET) is a very useful technique for medical diagnosis and drug development. Radiopharmaceuticals are a key element in PET techniques and one of the pivotal factors influencing the applications of PET. The aim of this Special Issue of Molecules is to report on the recent research work on a number of aspects of PET radiopharmaceuticals and their preclinical and clinical use. More specifically, the content of this Special Issue includes but is not limited to radiolabeling design, radiosynthesis, synthesis techniques, quality control methodologies, GMP production methods, product formulation, in vitro and in vivo preclinical PET evaluations, clinical evaluations, dosimetry, stability study and metabolite analysis, and modeling.
Format
- Hardback
License and Copyright
© 2021 by the authors; CC BY-NC-ND license
Keywords
kinetic analysis; Siglec-9; gallium-68; vascular adhesion protein; VAP-1; infection; inflammation; osteomyelitis; animal model; Staphylococcus aureus; multiple myeloma; positron emission tomography/computed tomography; radiopharmaceuticals; 18F-fluorodeoxyglucose; tetrazine ligation; PET; SPECT; gallium-68; indium-11; fluorine-18; positron emission tomography (PET), defluorination; isotopic exchange; silicon-based fluoride acceptor; bioorthogonal chemistry; tetrazine; inverse electron-demand Diels-Alder ligation; opioid; naloxone; overdose; fentanyl; carfentanil; [11C]carfentanil; positron emission tomography; receptor occupancy; pharmacokinetics; [18F]AlF; NOTA; NODAGA; PODS; thiol-reactive; linker; affibody molecule; bioconjugation; EGFR; tumor imaging; vulnerable plaque; molecular imaging; PET imaging; nanobody; single-domain antibody; sub-millimetre resolution; AlF-radiolabelling; preclinical radiopharmaceutical dosimetry; image-based internal dosimetry; OLINDA; MCT1/MCT4 lactate transporter inhibitor; [18F]FACH; radiation safety; sigma-1 receptor availability; orthotopic xenograft of glioblastoma in mouse; small animal Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI); (S)-(−)-[18F]fluspidine; imaging-based biomarker; SV2A protein; PET radiotracers; synaptic loss; radiochemistry; preclinical development; clinical outcomes; monocarboxylate transporters (MCTs); FACH; 18F-labeled analog of FACH; α-CCA; blood-brain barrier (BBB); positron emission tomography (PET) imaging; radiopharmaceuticals; peptides; positron emission tomography; proteolysis; metabolic stability